Knight Therapeutics Inc. Acquires Orphan Canada Inc. and Expands Business Development Capacity - Seite 3

About Joost van der Mark

Joost van der Mark is a seasoned healthcare executive with over two decades of experience in the biopharmaceutical industry. Prior to founding Orphan Canada, Joost was the VP of Business Development at Nycomed Canada (now Takeda Canada) with responsibility to lead the organization's business development initiative. Prior to joining Nycomed, Joost worked for Sanofi-Pasteur, where he successfully developed market access strategies, liaison with PMPRB and led the business development efforts. Joost started his career with Bayer HealthCare, progressing through various roles in clinical and commercial. Joost holds a M.Sc. in Physiology and Pharmacology from the University of Western Ontario and an M.B.A. from Schulich School of Business.

About Bourne Partners

Headquartered in Charlotte, NC, Bourne Partners is a financial advisory, investment and consulting firm founded in 2001 that focuses solely on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Originally founded as a pharmaceutical investment firm, Bourne Partners has evolved its service offerings in an effort to form enduring relationships with the healthcare and consumer companies it chooses to serve. For more information about Bourne Partners, please visit the company's website at www.bourne-partners.com.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares began trading on the TSX-V on March 3, 2014 and graduated to the TSX on April 29, 2014 under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or at www.sedar.com.

Knight Therapeutics Forward-Looking Statement

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the company's final application for listing on the TSX Venture Exchange and in two short form prospectuses which can be found on SEDAR at www.sedar.com, which investors should consult for additional information. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-4831
514-481-4116 (FAX)
[e-mail]
www.gud-knight.com